echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Yuheng pharmaceutical's new anticancer drug enters the clinical trial

    Yuheng pharmaceutical's new anticancer drug enters the clinical trial

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    It is reported that Yuheng pharmaceutical's new anticancer drug has received clinical approval and will officially enter the clinical trial stage Yuheng Pharmaceutical (002437 SZ) declared the clinical approval status of medetinib sulfate tablets (acceptance No.: cxhl1100445, cxhl1100446), a new chemical class 1.1 new drug (not yet marketed at home and abroad), which was changed to "approved pending certificate" recently According to the process, the company will receive the clinical approval of the new drug in the near future, which marks that the new drug will officially enter the market Enter the clinical trial stage According to the personage of medical investment promotion website, given that medicini is superior to imatinib in curative effect, and considering that imatinib has more researchers in China, the market prospect of medicini is expected to be more optimistic in the future However, the person in charge of drug registration of a pharmaceutical company thinks that the approval of new drugs that are just starting clinical will face the competition of prescription right in the future, so it is not so easy to occupy the market According to relevant people, the advantage of Yuheng lies in sales, and the company is trying to change the situation that the proportion of deer and melon polypeptide injection is too large, and is seeking to enrich its product line It is reported that in addition to the above-mentioned heavyweight new drugs, the company is also developing new drugs, such as Qinlongkusu, a new Chinese medicine, which is mainly used to treat hepatitis In the development of medical field, cancer is a kind of death disease, which seriously threatens our health The treatment method has become a difficult problem in the medical field There are many new anticancer drugs emerging in the pharmaceutical market, but meditinib sulfate, a new anticancer drug in Yuheng pharmaceutical industry, is favored by pharmaceutical agents, hoping to compete for its agency right and create many profits for itself The attention of this medicine will be a cornerstone for it to enter the pharmaceutical market Original title: new anticancer drugs of various pharmaceutical enterprises are emerging in the pharmaceutical industry
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.